An iPS cell, or induced pluripotent stem cell (iPSC), is a type of stem cell created by reprogramming an ordinary adult cell back into an embryo-like state. Once reprogrammed, these cells can grow into virtually any cell type in the human body: heart muscle, brain neurons, liver tissue, and more. The technology was first demonstrated in mice in 2006 and in humans in 2007 by Japanese researcher Shinya Yamanaka, a breakthrough that earned him the Nobel Prize in Physiology or Medicine in 2012.
How Adult Cells Become Stem Cells
The process starts with a simple cell, typically a skin cell or blood cell taken from a donor. Scientists introduce four specific proteins, known as the Yamanaka factors (Oct3/4, Sox2, Klf4, and c-Myc), into that cell. These proteins act like a reset button, stripping away the cell’s specialized identity and returning it to a flexible, embryonic-like state. The result is a cell that can multiply indefinitely and be coaxed into becoming nearly any tissue type.
Yamanaka’s original method used viruses to deliver those four proteins into the cell’s DNA, which worked but carried a risk: the viral DNA could insert itself into the wrong spot in the genome and potentially trigger cancer. Since then, several safer delivery methods have emerged. Sendai virus vectors stay outside the cell’s nucleus entirely, never integrating into the genome and gradually disappearing as the cell divides. Episomal vectors offer a virus-free option that’s both efficient and inexpensive. The current gold standard for clinical use involves modified messenger RNA molecules, which deliver reprogramming instructions temporarily and leave no trace in the cell’s DNA.
Efficiency has improved dramatically as well. Early methods converted a tiny fraction of cells. Optimized RNA-based techniques can now reprogram over 90% of individually plated skin cells into iPSCs, generating thousands of stem cell colonies from just 500 starting cells.
Why iPSCs Matter More Than Embryonic Stem Cells
Before iPSCs existed, the only way to get pluripotent stem cells was to harvest them from human embryos, destroying the embryo in the process. This created a deep ethical and political divide that stalled research for years. iPSCs bypass that problem entirely. They’re made from a patient’s own skin or blood cells, so no embryo is involved at any stage. The process fully respects the dignity of the person who supplied the cells.
Beyond ethics, iPSCs solve a major biological problem. Embryonic stem cells come from a donor, meaning any tissue grown from them can be rejected by the recipient’s immune system, just like a mismatched organ transplant. iPSCs made from a patient’s own cells are a genetic match. In primate studies directly comparing self-derived (autologous) and donor-derived (allogeneic) iPSC transplants in the brain, the self-derived cells triggered only a minimal immune response and didn’t require immunosuppressive drugs. Donor-derived grafts, by contrast, activated immune cells and attracted white blood cells to the graft site. Significantly more neurons survived in the self-derived transplants.
Modeling Diseases in a Dish
One of the most immediately useful applications of iPSCs isn’t transplanting them into people. It’s using them to study diseases in the lab. Scientists can take skin cells from a patient with a genetic disorder, reprogram those cells into iPSCs, and then grow them into the specific cell type affected by the disease. The result is a living model of that patient’s illness in a petri dish.
This approach is already being used across a range of conditions. Researchers have created iPSC-derived neurons from patients with Parkinson’s disease and Alzheimer’s disease, insulin-producing cells from patients with juvenile-onset type 1 diabetes, muscle cells from patients with Duchenne muscular dystrophy, and brain cells from patients with rare neurological conditions like childhood cerebral adrenoleukodystrophy. These disease-specific cell models let researchers watch how a disease develops at the cellular level and test potential drugs directly on affected human tissue, without needing to rely solely on animal models.
Clinical Trials and Therapeutic Use
The most watched clinical application right now involves Parkinson’s disease. In Parkinson’s, specific dopamine-producing neurons in the brain progressively die. The idea is straightforward: take a patient’s own cells, reprogram them into iPSCs, grow those into dopamine neurons, and transplant them back into the brain. A Phase 1 clinical trial is currently testing exactly this approach, evaluating the safety of autologous iPSC-derived dopamine neuron transplants in six participants.
This trial is notable because it uses each patient’s own cells, meaning immunosuppressive drugs may not be needed after transplantation. That’s a significant practical advantage, since immunosuppression carries its own long-term health risks.
Safety Concerns and Genetic Stability
The biggest open question with iPSC therapies is safety, particularly the risk of transplanted cells growing uncontrollably. The same reprogramming factors that make iPSCs so versatile have known links to cancer. And the reprogramming process itself can introduce genetic mutations, including changes in chromosome number and structural rearrangements that are detectable through standard genetic testing.
This isn’t a theoretical concern. In 2015, a planned human trial of iPSC-derived retinal cells in Japan was cancelled after genetic mutations were found in the iPSCs prepared for transplantation. There was no clear evidence those specific mutations would have caused harm, but researchers judged the risk unacceptable. In animal studies, iPSC-derived brain cells have formed tumors after long-term observation, underscoring the need for extended follow-up in any patient who receives these cells.
No evidence-based guidelines yet exist for testing whether iPSC-derived cell products will form tumors. Researchers currently rely on a combination of genetic sequencing and tumor formation assays in animals, but the field is still working out what level of genetic variation is acceptable for clinical use.
Scaling Up Production
For iPSC therapies to treat large numbers of patients, scientists need to grow enormous quantities of cells reliably. A single therapeutic dose for conditions like heart failure or Parkinson’s disease can require billions of cells. Traditional lab culture methods, using flat dishes and flasks, can’t produce cells at that scale.
Bioreactor systems are the leading solution. These are controlled vessels that grow cells in three-dimensional clusters called spheroids, suspended in liquid culture medium. A bioreactor using a gentle back-and-forth mixing method recently produced roughly 10 billion iPSCs from just 2 liters of culture while maintaining the cells’ stem cell properties. Controlling the mixing speed turns out to be critical: too fast and cells get damaged, too slow and spheroids grow too large, starving cells at the center of oxygen and nutrients. These systems are still being refined, but the basic proof of concept for industrial-scale iPSC production is established.